Table 1:
Population Pharmacokinetic Estimates for Tenofovir Disoproxil Fumarate (TDF)
| Parameter (units) | Final NONMEM Estimate | Median Bootstrap Estimate | Bootstrap 95% CI | %RSE |
|---|---|---|---|---|
| Ka (hr−1)* | 3 | 3 | -- | -- |
| CL/F (L/hr) | 40.4 | 39.7 | (26.1 – 50.3) | 17.7% |
| V/F (L) | 161 | 154 | (26.7 – 291) | 47.6% |
| Q/F (L/hr) | 73.6 | 64.0 | (20.8 – 119) | 44.8% |
| V2/F (L) | 618 | 574 | (275 – 839) | 29.4% |
| K24 (hr−1) | 0.0344 | 0.0394 | (0.00567 – 0.106) | 75.0% |
| K40 (hr−1) | 0.0309 | 0.0364 | (0.00577 – 0.0910) | 72.7% |
| K25 (hr−1) | 0.0152 | 0.0114 | (0.00234 – 0.0153) | 80.8% |
| TAU1 (hr−1) | 0.001 | 0.00100 | (0.000994 – 0.00103) | 1030% |
| K70 (hr−1) | 0.0126 | 0.00992 | (0.00208 – 0.0127) | 99.9% |
| K26 (hr−1) | 0.0263 | 0.0248 | (0.00608 – 0.0507) | 59.5% |
| TAU2 (hr−1) | 0.0845 | 0.0864 | (0.0409 – 0.455) | 138% |
| K80 (hr−1) | 0.0844 | 0.0812 | (0.0236 – 0.159) | 63.4% |
| ω on CL/F (%CV) | 26.3% | 24.0% | (8.98% – 35.7%) | 49.8% |
| ω on V/F (%CV) | 82.8% | 84.7% | (15.5% – 166%) | 95.2% |
| ω on K40 (%CV) | 42.0% | 37.8% | (8.36% – 65.0%) | 64.6% |
| ω on K50 (%CV) | 88.9% | 83.5% | (50.1% – 110%) | 35.0% |
| ο on BP (%CV) | 21.4% | 21.1% | (13.8% – 29.5%) | 42.2% |
| ο on PBMC (%CV) | 52.2% | 51.5% | (39.5% – 66.3%) | 24.8% |
| ο on SP (%CV) | 43.9% | 44.1% | (38.0% – 49.5%) | 12.7% |
| ο on SMC (%CV) | 145% | 137% | (99.4% – 168%) | 24.9% |
*
Fixed Parameter
95% CI – 95% Confidence Interval of bootstrap estimate
%RSE – Relative Standard Error in Percentage Terms
ω – Interindividual Variability
ο – Residual Variability
%CV – Coefficient of Variation in Percentage Terms